These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 15473294)

  • 21. Celecoxib and cardiovascular risks.
    Brophy JM
    Expert Opin Drug Saf; 2005 Nov; 4(6):1005-15. PubMed ID: 16255660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COX-2 inhibitors and hypercoagulability.
    Farkouh ME
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):35-6. PubMed ID: 16166966
    [No Abstract]   [Full Text] [Related]  

  • 23. Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?
    Brune K; Furst DE
    Rheumatology (Oxford); 2007 Jun; 46(6):911-9. PubMed ID: 17459958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of cyclooxygenase inhibition on the gastrointestinal tract.
    Radi ZA; Khan NK
    Exp Toxicol Pathol; 2006 Nov; 58(2-3):163-73. PubMed ID: 16859903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COX inhibition for tocolysis and its effect on the neonate.
    Jeyaraj B
    J Perinatol; 2007 Jun; 27(6):395; author response 395-6. PubMed ID: 17522690
    [No Abstract]   [Full Text] [Related]  

  • 26. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation.
    Borgdorff P; Tangelder GJ; Paulus WJ
    J Am Coll Cardiol; 2006 Aug; 48(4):817-23. PubMed ID: 16904555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Constriction of the ductus arteriosus by selective inhibition of cyclooxygenase-1 and -2 in near-term and preterm fetal rats.
    Toyoshima K; Takeda A; Imamura S; Nakanishi T; Momma K
    Prostaglandins Other Lipid Mediat; 2006 Mar; 79(1-2):34-42. PubMed ID: 16516808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular complications of COX2 selective inhibitors cause considerable concern.
    Hedner T; Himmelmann A
    Blood Press; 2004; 13(5):260-1. PubMed ID: 15545147
    [No Abstract]   [Full Text] [Related]  

  • 30. Risk of perioperative COX-2-inhibitor treatment: is a systematic review appropriate?
    Kehlet H
    N Z Med J; 2006 Jan; 119(1228):U1836. PubMed ID: 16462937
    [No Abstract]   [Full Text] [Related]  

  • 31. [COX-2 inhibitors and data interpretation].
    Raeder J
    Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2672; author reply 2672. PubMed ID: 16215622
    [No Abstract]   [Full Text] [Related]  

  • 32. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.
    Davies NM; Jamali F
    J Pharm Pharm Sci; 2004 Oct; 7(3):332-6. PubMed ID: 15576013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Precaution, cyclooxygenase inhibition, and cardiovascular risk.
    Ritter JM; Harding I; Warren JB
    Trends Pharmacol Sci; 2009 Oct; 30(10):503-8. PubMed ID: 19762092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COX-2 inhibitors--second, do some good.
    Harrison A
    N Z Med J; 2005 Apr; 118(1212):U1395. PubMed ID: 15806191
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.
    Burdan F
    Toxicology; 2005 Jul; 211(1-2):12-25. PubMed ID: 15863244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo.
    Patel NS; Cuzzocrea S; Collino M; Chaterjee PK; Mazzon E; Britti D; Yaqoob MM; Thiemermann C
    Eur J Pharmacol; 2007 May; 562(1-2):148-54. PubMed ID: 17343844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig.
    Timmers L; Sluijter JP; Verlaan CW; Steendijk P; Cramer MJ; Emons M; Strijder C; Gründeman PF; Sze SK; Hua L; Piek JJ; Borst C; Pasterkamp G; de Kleijn DP
    Circulation; 2007 Jan; 115(3):326-32. PubMed ID: 17210840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COX-2 inhibitors--first, do no harm.
    Weatherall M; Aldington S; Shirtcliffe P; Caldwell B; Beasley R
    N Z Med J; 2005 Mar; 118(1211):U1359. PubMed ID: 15778758
    [No Abstract]   [Full Text] [Related]  

  • 39. [Intravenous immunoglobulins commercialized in Spain and potential risk of acute renal failure].
    Escoms Moreno MC; Riera Molist N; Montoro Ronsano JB
    Med Clin (Barc); 1999 Sep; 113(8):318. PubMed ID: 10603586
    [No Abstract]   [Full Text] [Related]  

  • 40. [Caveat emptor! Let the buyer beware!].
    Schneede J
    Tidsskr Nor Laegeforen; 2002 Aug; 122(19):1919. PubMed ID: 12362721
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.